The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
1. Extension of U.S. – EU Tariff Deadline
The United States has postponed the implementation of a proposed 50% tariff on European Union goods from June 1 to July 9, 2025, allowing additional time for trade negotiations. This decision follows discussions between U.S. and EU officials aimed at resolving trade tensions.
2. U.S. – India Trade Negotiations Continue
High-level trade talks between the United States and India continued in Washington, D.C., with both sides aiming to finalize the first phase of a bilateral trade agreement before the expiration of the 90-day tariff pause in early July. Discussions have focused on tariff exemptions and enhancing market access
3. U.S. – Korea Trade Update
The United States and South Korea are working toward a comprehensive trade agreement, informally known as the “July Package,” targeted for completion by July 8, 2025. The framework aims to resolve tariff disputes and address longstanding trade imbalances.
Reference:
US Tariffs Updates Impact Global Trade
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
N,N′-Dimethylethylenediamine (DMEDA) is an organic chemical compound belonging to the diamine family. It contains two nitrogen atoms, each bearing a methyl group, connected by a two-carbon chain.
Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.
The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.